Fig. 2: TCF4 acts as a repressor of ferroptosis in GC cells.
From: Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
a Cell viability of GC cells expressing sgNC or sg-TCF4 treated with different concentrations of erastin for 24 h. b Cell viability of GC cells transfected with control or TCF4-coding plasmid and treated with erastin for 24 h. c Cell death measurement of AGS expressing sgNC or sg-TCF4 treated with erastin (20 μM) in the absence or presence of ferrostatin-1 (2 μM), liproxstatin-1 (1 μM), Z-VAD-FMK (10 μM), necrosulfonamide (0.5 μM), or 3-methyladenine (250 μM) for 24 h. d Cell viability of AGS expressing sgNC or sg-TCF4 treated with erastin (50 μM) in the absence or presence of ferrostatin-1 (2 μM), liproxstatin-1 (1 μM), Z-VAD-FMK (10 μM), necrosulfonamide (0.5 μM), or 3-methyladenine (250 μM) for 24 h. e MDA production in GC cells expressing sgNC or sg-TCF4. f MDA production in GC cells transfected with control or TCF4-coding plasmid. Data are presented as the mean ± SD of three independent experiments. The p-values in panels a–d were calculated by two-way ANOVA. The p-values in panel e were calculated by one-way ANOVA. The p-values in panle f were calculated by Student’s t-test and one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
